REGENERON PHARMACEUTICALS, INC. Cash and Restricted Cash
REGENERON PHARMACEUTICALS, INC. (REGN) had Cash and Restricted Cash of $2.47 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-30
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.47B.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.97B.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.12B.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.51B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $2.47B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $2.97B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $3.12B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $2.51B 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $2.02B 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $3.09B 10-Q · filed 2026-04-29 | |
| 2024-12-31 | $2.49B 10-Q · filed 2026-07-30 | |
| 2024-09-30 | $2.01B 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $1.93B 10-Q · filed 2025-08-01 | |
| 2024-03-31 | $2.61B 10-Q · filed 2025-04-29 | |
| 2023-12-31 | $2.74B 10-K · filed 2026-02-04 | |
| 2023-09-30 | $2.16B 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $1.95B 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $3.93B 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $3.12B 10-K · filed 2026-02-04 | |
| 2022-09-30 | $3.50B 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $3.41B 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $3.36B 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $2.90B 10-K · filed 2025-02-05 | |
| 2021-09-30 | $3.44B 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $2.08B 10-Q · filed 2022-08-03 | |
| 2021-03-31 | $1.45B 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $2.21B 10-K · filed 2024-02-05 | |
| 2020-09-30 | $1.59B 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $2.00B 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $2.22B 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $1.63B 10-K · filed 2023-02-06 | |
| 2019-09-30 | $1.40B 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.06B 10-Q · filed 2020-08-05 | |
| 2019-03-31 | $1.72B 10-Q · filed 2020-05-05 | |
| 2018-12-31 | $1.48B 10-K · filed 2022-02-07 | |
| 2018-09-30 | $1.10B 10-Q · filed 2019-11-05 | $1.10B 10-Q · filed 2018-11-06 |
| 2018-06-30 | $930.40M 10-Q · filed 2019-08-06 | $930.38M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $1.03B 10-Q · filed 2019-05-07 | $1.03B 10-Q · filed 2018-05-03 |
| 2017-12-31 | $825.20M 10-K · filed 2021-02-08 | $825.23M 10-Q · filed 2018-05-03 |
| 2017-09-30 | $804.57M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $756.81M 10-Q · filed 2018-08-02 | |
| 2017-03-31 | $824.27M 10-Q · filed 2018-05-03 | |
| 2016-12-31 | $547.70M 10-K · filed 2020-02-07 | $547.70M 10-Q · filed 2018-05-03 |
| 2015-12-31 | $809.10M 10-K · filed 2019-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |